RxDoctor Payments Data

Shelle Schumacher

Interventional Pain Medicine · Lafayette, INNPI 1134895188

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 57.5% of the total. 2025 is the largest year on record at $588, more than ten times the $29 reported in 2023. That places this record below the midpoint for interventional pain medicine clinicians in IN, where the typical reported total is $4,157.

$735in general payments, 2019–2025

Across 45 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$422
  • Pfizer$56
  • Tersera Therapeutics LLC$43
  • MML US, Inc.$41
  • Boston Scientific$36
  • Valinor Pharma, LLC$34
  • plus $102 from 6 others

What the payments were for

  • Food & beverage$735100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie26$422
Pfizer3$56
Tersera Therapeutics LLC2$43
MML US, Inc.4$41
Boston Scientific2$36
Valinor Pharma, LLC2$34
Azurity Pharmaceuticals, Inc.1$22
Lundbeck LLC1$20
Vertex1$19
Si-bone, Inc.1$15
Tonix Medicines, Inc.1$15
Vertos Medical, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$735 in reported general payments places this provider in the 15th percentile of 68 interventional pain medicine providers in Indiana.

See all interventional pain medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$48,690
Medicare patients
192
Services billed
2,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen580$15,133
BelbucaBuprenorphine Hcl13$12,731
Fentanyl82$10,398
HorizantGabapentin Enacarbil13$8,697
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen314$8,125
Buprenorphine17$4,861
Morphine Sulfate101$3,160
Pregabalin83$3,139
Hydromorphone Hcl133$2,127
Morphine Sulfate ErMorphine Sulfate65$1,338
Naloxone Hcl16$1,198
Tramadol Hcl134$1,175
Oxycodone Hcl77$1,161
Gabapentin129$1,153
Tizanidine Hcl73$905

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →